Of note, in our study, clinical studies showed that the expression of PLA2G16 is markedly related to breast cancer malignancy, recurrence, chemo-resistance and poor prognosis in patients, suggesting that PLA2G16 is a useful therapeutic target to eradicate BCSCs and improve the poor prognosis of patients with breast cancer. Here, PLAAT3 is linked to breast cancer.